By Pushkala Aripaka

(Reuters) -AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugmaker’s long-term sales strategy.

The company is aiming for potential approvals in 2026 for the drug, baxdrostat, starting with the U.S. and the EU, said Ruud Dobber, president of AstraZeneca’s biopharmaceuticals unit, ahead of a presentation of advanced trial data at a medical conference on Saturday.

Baxdrostat targets blood pressure-regulating hormone aldosterone, a novel approach compared with older treatments like diuretics and ACE inhibitors, which do not address hormonal drivers.

AstraZeneca expects peak annual sales for the drug to exceed $5 billion.

Keenl

See Full Page